RLMD Relmada Therapeutics Inc

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.

Conference Call and Webcast Information:

  • Date: Thursday, August 7, 2025 at 4:30 PM ET
  • Participant Dial-in (US): 1-877-407-0792
  • Participant Dial-in (International): 1-201-689-8263
  • Conference: 13754263
  • Webcast Access:

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit

Investor Contact:

Brian Ritchie

LifeSci Advisors

Media Inquiries:

Corporate Communications



EN
31/07/2025

Underlying

RLMDRelmada Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relmada Therapeutics Inc

 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max K...

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous sy...

October 7, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Listing Rule”). To regain compliance...

September 16, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Issues Mid-Year CEO Letter to Shareholders CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a truly transformational year for Relmada Therapeutics. With the year now well into its second half, I am pleased to share an update on our recent progress and to thank you f...

September 10, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC 6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 P...

August 7, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Report Second Quarter 2025 Financial Results o...

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information: Dat...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch